$TLRY

FALTISCHEK DENISE M purchased $12K of TLRY

FALTISCHEK DENISE M (Chief Strategy Officer) purchased 2,500 shares of Tilray Brands, Inc. (TLRY) at $4.78 on 2026-08-03.

Original reporting
SEC EDGAR · FALTISCHEK DENISE M
Published Aug 4, 2026, 2:58 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 3:16 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TLRY
Bullish
medium confidence
Mentioned
$TLRY
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TLRYBullishLow
01

Why it matters

A new insider open-market purchase was reported, which can slightly influence sentiment but does not change fundamentals on its own.

02

Market read

Traders may note the insider buy, but the disclosed value is small and there is no accompanying corporate catalyst.

03

What to watch

No 10b5-1 plan is cited, but the filing does not explain motivation, timing constraints, or whether the buy is part of a broader pattern.

Relevance 4/10Novelty 3/10Timing: SEC Form 4 filed today, after-hours/late session visibility

Background

This is an SEC Form 4 insider transaction disclosure for Tilray Brands, Inc.

Company-level read

Ticker impact

$TLRYBullishMedium confidence
Context

Tilray Brands disclosed via Form 4 that Chief Strategy Officer Denise M. Faltischek bought 2,500 shares at $4.7800 on 2026-08-03.

Expected impact

Likely limited near-term impact; may add small incremental bullish sentiment rather than a catalyst.

Evidence & confidence

Form 4 is primary-source and new today, but the transaction value (~$12k) is small relative to typical market-moving thresholds and provides no guidance, deal, or operational change.

Market effects

No clear sector read-through; this is company-specific insider activity without broader regulatory or industry developments.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine liquidity or diversification rather than a strong fundamental signal, especially at small sizes.

Key entities

  • Tilray Brands, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Denise M. Faltischek

    Chief Strategy Officer who purchased 2,500 shares.

Related articles

$TLRYMed

Tilray Brands (TLRY) Is Up 5.7% After Narrower Loss, ESOP Shelf Filing and M&A Signal

Tilray Brands reported Q4 sales of US$281.71 million and full-year sales of US$915.45 million for the year ended May 31, 2026, with a substantially smaller net loss than the prior year. The company also filed a US$47.69 million shelf registration for 11,355,231 common shares tied to its ESOP. Management said at-the-market equity proceeds may fund acquisitions, including deals like BrewDog.

$TLRYMed

Tilray Brands Q4 Earnings Call Highlights

Tilray Brands (NASDAQ: TLRY) reported fiscal 2026 results on its Q4 earnings call. Net loss narrowed to $105.2M ($1.09/share) from about $2.2B in fiscal 2025. Adjusted net income rose 87% to $12.2M. Cannabis and distribution revenue grew, BrewDog added beverage revenue, and Tilray guided adjusted EBITDA of $68M to $75M for fiscal 2027.

$TLRYMed

Tilray Brands reports record US$915.5M revenue in Fiscal 2026

Tilray Brands reported record fiscal 2026 revenue of US$915.5M, up 11% from US$821.3M, driven by cannabis, beverage, distribution and wellness. Beverage net revenue rose 6% to US$254.0M, with Q4 beverage revenue up 61% to US$105M. Adjusted EBITDA increased to US$61.1M. Tilray completed a £33M BrewDog acquisition in March. It forecasts fiscal 2027 adjusted EBITDA of US$68M to US$75M.

$TLRYMedAI 8/10

Tilray Brands Q4 revenue beats estimates by 10.7%, shares rise 2.23%

Tilray Brands reported Q4 net revenue of $281.7 million for the period ended May 31, up 10.7% versus the $254.53 million consensus estimate, and shares rose 2.23% to $4.12 after hours. Adjusted EPS was $0.05, missing the $0.21 consensus. For FY26, net revenue rose 11% to $915.5 million; adjusted EBITDA increased to $61.1 million.